Janssen is collaborating with Cidara Therapeutics, a JLABS @ San Diego alumni resident, with the aim to develop new treatments that could provide universal, seasonal protection against all seasonal and pandemic strains of influenza, which causes up to 650,000 deaths worldwide each year.1
This collaboration brings together Janssen’s expertise in the development and commercialization of vaccines and therapies for respiratory viral diseases, with Cidara’s Cloudbreak® platform and expertise in developing long-acting therapeutics (called drug-Fc conjugates (DFCs)), designed to transform the standard of care for patients facing serious diseases such as viral infections and cancer. Together the companies began Phase 1 in March 2022.
1CDC, Vaccine Effectiveness: How Well Do Flu Vaccines Work?,
Accessed, Date: October 17, 2021